Implementation of HIV-related clinical research in the international setting

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue SUPPL.1, 2014, Pages

  Godfrey, Catherine ^a   Schouten, Jeffrey T ^b   Swindells, Susan ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b USA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

ACTG; Implementation; International clinical research

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); EDITORIAL; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL RELATIONS; LEADERSHIP; NATIONAL HEALTH ORGANIZATION; PREVENTION STUDY; PRIORITY JOURNAL; RESEARCH PRIORITY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; EPIDEMIC; FUNDING; INTERNATIONAL COOPERATION; LABORATORY; NEUROLOGICAL COMPLICATION; PRACTICE GUIDELINE;

ANTIRETROVIRUS AGENT;

EID: 84890933193     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000032     Document Type: Editorial

References (16)

1. Benson C. NIH AIDS Clinical Trials Group (ACTG) Network Therapeutic Research in Resource-Limited Settings. 2010. Available at: http:// regist2.virology-education.com/4thINTEREST/docs/34-Benson.pdf. Accessed September 20, 2013.
2. Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9: e1001290.
3. Robertson K, Jiang H, Kumwenda J, et al. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study A5199, the International Neurological Study. Clin Infect Dis. 2012;55: 868-876.
4. McMahon DK, Zheng L, Hitti J, et al. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. Clin Infect Dis. 2013;56: 1044-1051.
5. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010;363: 1499-1509.
6. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365: 1492-1501.
7. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365: 1471-1481.
8. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011; 365: 1482-1491.
9. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365: 493-505.
10. Cohen J. HIV treatment as prevention. Science. 2011;334:1628.
11. Grinsztejn B, Ribaudo H, Cohen MS, et al; and the HPTN 052 Protocol Team. Effects of early versus delayed initiation of antiretroviral therapy (ART) on HIV clinical outcomes: results from the HPTN 052 randomized clinical trial. Paper presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011; Rome, Italy.
12. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363: 257-265.
13. Morin SF, Morfit S, Maiorana A, et al. Building community partnerships: case studies of Community Advisory Boards at research sites in Peru, Zimbabwe, and Thailand. Clin Trials. 2008;5: 147-156. (Pubitemid 351682524)
14. Dickert N, Sugarman J. Ethical goals of community consultation in research. Am J Public Health. 2005;95: 1123-1127. (Pubitemid 40880859)
15. Rennie S, Sugarman J. Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach. J Med Ethics. 2010;36: 810-815.
16. Kagan JM, Rosas SR, Siskind RL, et al. Community-researcher partnerships at NIAID HIV/AIDS clinical trials sites: insights for evaluation and enhancement. Prog Community Health Partnersh. 2012;6: 311-320.